In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.
about
Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cellsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciComparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.Nonribosomal peptide synthetases involved in the production of medically relevant natural products.Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.Daptomycin.Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureusLipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Emerging drugs for bacterial urinary tract infections.Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrityDaptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.Cell wall assembly in Bacillus subtilis: how spirals and spaces challenge paradigms.Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia.Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization.Pre-clinical experience with daptomycin.Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.Cardiolipin prevents membrane translocation and permeabilization by daptomycin.Current use of daptomycin in cardiac surgery and postoperative intensive care.Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans.Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocarGenetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.Antibacterial and membrane-damaging activities of β-bungarotoxin B chain.
P2860
Q24682375-29BD896B-645A-447A-8700-BBE54FC5BCAFQ26853465-A0BA7FEA-92F4-4B13-B72E-3CFE1C8EA679Q34057457-A74E05E6-5183-4BD8-952D-02E4B572983EQ35090396-73CC087F-6E2C-4764-BA30-EA6EC09754C5Q35166213-4842C383-8A13-468F-B9B6-84B350912C82Q35637066-10116129-61DE-4500-9333-922B38729A30Q35701450-E9E36EE9-75F9-4B35-BC4F-22F189E840B7Q35782816-E1340CC0-9733-41C8-A971-E25E69235DFAQ35850231-504DC068-6B4E-4837-A784-0789FD6DAE3BQ35871928-C8645785-411E-4789-86F4-7B221AF252AEQ36150606-27C8C0D7-C511-4992-B7F3-640FA9FBD3E9Q36295305-297730F2-5CF1-45C3-A06E-E0DECB467369Q36407206-535D48A1-9E12-47CC-BD0B-7155FE29F5BEQ36475457-6C3269F7-1C69-4360-B08F-E403FA501ECCQ36482313-27790289-57CD-4452-A624-9D6CC7F9EAA0Q36482900-7973983D-0465-45D9-B062-9C44F8746435Q37284356-5B82742A-2BAB-478B-AF93-84322C2E6D47Q37417749-D27C10E9-47F8-4DA8-8D4E-4CC44C0E5D28Q37727568-9791FF39-CA2F-421E-9912-95D9E54255BDQ38086339-9A91FC0D-2747-4F11-B08B-2603B6199404Q40982610-F57E2767-E797-4C8F-9D29-205D31651A37Q41570351-1EE07585-0C29-4B9D-9F13-2150093A9291Q41884192-03E12182-B292-4EC6-89C5-092D27DADF53Q42112490-192BD0B3-D9EC-4210-809C-8941CB299F5AQ42112713-6932D5AF-D813-4806-8AC3-989B655CAB06Q42363645-2D871A62-5D7C-4312-9996-605184BADCDBQ44918045-0E954F66-9B75-4A67-B2CE-9116CB7FB292Q46471549-F6762238-76F8-45A0-893A-E0A63B9A90D5Q46832044-4E0B0D50-5A6D-446D-B404-28D53B1888FDQ54323992-C2C9A563-128A-4695-8BBB-C68653BA840E
P2860
In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@en
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@nl
type
label
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@en
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@nl
prefLabel
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@en
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@nl
P2093
P2860
P1476
In vitro bactericidal activiti ...... ipoteichoic acid biosynthesis.
@en
P2093
Jared A Silverman
Jeffrey Alder
Valerie Laganas
P2860
P304
P356
10.1128/AAC.47.8.2682-2684.2003
P407
P577
2003-08-01T00:00:00Z